297 related articles for article (PubMed ID: 38774882)
21. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
Sa H; Shi Y; Ding C; Ma K
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
[TBL] [Abstract][Full Text] [Related]
23. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.
Lin YT; Liu YN; Wu SG; Yang JC; Shih JY
Clin Lung Cancer; 2017 May; 18(3):324-332.e1. PubMed ID: 28089594
[TBL] [Abstract][Full Text] [Related]
24. [Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition)].
Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):325-337. PubMed ID: 37316442
[TBL] [Abstract][Full Text] [Related]
25. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
Duan J; Wu L; Yang K; Zhao J; Zhao Y; Dai X; Li M; Xie Y; Yao Y; Zhao M; Zhou C; Ren X; Liu Z; Pan Y; Li Y; Liu B; Cheng Y; Miao L; Yu Q; Zhang Z; Liu X; Cui J; Zhang Y; Zhang L; Li X; Li X; Shen B; Chen B; Zeng S; Li B; Hu Y; Li L; Wu R; Song Q; Wang J
J Thorac Oncol; 2024 Feb; 19(2):314-324. PubMed ID: 37776953
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.
Zwierenga F; van Veggel BAMH; van den Berg A; Groen HJM; Zhang L; Groves MR; Kok K; Smit EF; Hiltermann TJN; de Langen AJ; van der Wekken AJ
Cancer Treat Rev; 2023 Nov; 120():102628. PubMed ID: 37797348
[TBL] [Abstract][Full Text] [Related]
27. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.
Shaffer W; Kobayashi IS; Sentana-Lledo D; Sundararaman S; Lee MD; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Lung Cancer; 2023 Jul; 181():107250. PubMed ID: 37196448
[TBL] [Abstract][Full Text] [Related]
28. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
29. Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Pan B; Liang J; Shi H; Rao K; Guo W; Zhan C
Thorac Cancer; 2023 Nov; 14(33):3247-3258. PubMed ID: 37795778
[TBL] [Abstract][Full Text] [Related]
30. [Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].
Yang WJ; Gao YB; Qiu T; Wang YG; He J
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):732-736. PubMed ID: 29061015
[No Abstract] [Full Text] [Related]
31. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
33. The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives.
Dorta-Suárez M; de Miguel M; Amor-Carro O; Calderón JM; González-Ortega M; Rodríguez-Abreu D
Cancer Treat Rev; 2024 Mar; 124():102671. PubMed ID: 38281403
[TBL] [Abstract][Full Text] [Related]
34. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC.
Ou SI; Hong JL; Christopoulos P; Lin HM; Vincent S; Churchill EN; Soeda J; Kazdal D; Stenzinger A; Thomas M
J Thorac Oncol; 2023 Jun; 18(6):744-754. PubMed ID: 36738930
[TBL] [Abstract][Full Text] [Related]
35. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah MP; Aredo JV; Padda SK; Ramchandran KJ; Wakelee HA; Das MS; Neal JW
Clin Lung Cancer; 2022 Mar; 23(2):e148-e153. PubMed ID: 34391686
[TBL] [Abstract][Full Text] [Related]
36. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
Sari M; Aydiner A
J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
[TBL] [Abstract][Full Text] [Related]
37. Non-small cell lung cancer with
Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
Imai H; Minemura H; Sugiyama T; Yamada Y; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2018 Jul; 82(1):119-127. PubMed ID: 29737372
[TBL] [Abstract][Full Text] [Related]
39. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
[TBL] [Abstract][Full Text] [Related]
40. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
